Stefan Reichert1, Ulrike Triebert2, Alexander Navarrete Santos3, Britt Hofmann4, Hans-Günter Schaller2, Axel Schlitt5, Susanne Schulz2. 1. Department of Operative Dentistry and Periodontology, Martin-Luther-University Halle-Wittenberg, Germany. Electronic address: stefan.reichert@uk-halle.de. 2. Department of Operative Dentistry and Periodontology, Martin-Luther-University Halle-Wittenberg, Germany. 3. Center for Medical Basic Research, Martin-Luther-University Halle-Wittenberg, Germany. 4. Department of Internal Medicine III, Heart Centre of the University Clinics Halle (Saale), Martin-Luther-University Halle-Wittenberg, Germany; Department of Cardiothoracic Surgery, Heart Centre of the University Clinics Halle (Saale), Martin-Luther-University Halle-Wittenberg, Germany. 5. Department of Internal Medicine III, Heart Centre of the University Clinics Halle (Saale), Martin-Luther-University Halle-Wittenberg, Germany; Department of Cardiothoracic Surgery, Heart Centre of the University Clinics Halle (Saale), Martin-Luther-University Halle-Wittenberg, Germany; Department of Cardiology, Paracelsus Harz-Clinic Bad Suderode, Germany.
Abstract
BACKGROUND AND AIMS: Soluble RAGE (sRAGE) serum level could be a biomarker for atherosclerosis and subsequent diseases such as cardiovascular disease (CVD). Therefore, we wanted to investigate whether peripheral sRAGE level is associated with new cardiovascular events among patients with CVD using the Cox's regression analysis. METHODS: In this three-year longitudinal cohort study, 1002 in-patients with angiographically proven CVD were included. In 933 patients, sRAGE levels were determined by a commercial available ELISA kit at the time of baseline examination. The combined endpoint was defined as myocardial infarction, stroke/TIA (non-fatal, fatal), and cardiovascular death. For risk analysis, sRAGE values were distributed in quartiles. For generation of adjusted hazard ratios (HR), other risk factors for CVD, such as age, gender, current smoking, body mass index, diabetes, hypertension, dyslipoproteinemia, family history of CVD, severe periodontitis, serum levels for C-reactive protein and interleukin-6, were recorded. RESULTS: 886 patients completed the 3-year follow-up. The overall incidence of the combined endpoint was 16%. Patients with sRAGE levels >838.19 pg/ml (fourth quartile) had the highest incidence of recurrent CVD events (24.9% versus 13.1%, p < 0.0001). In multivariate Cox regression with respect to further confounders for CVD, the association between sRAGE and new CVD events was confirmed (HR = 1.616, 95% CI 1.027-2.544, p = 0.038). CONCLUSIONS: Elevated sRAGE serum level is associated with further adverse events in patients with CVD.
BACKGROUND AND AIMS: Soluble RAGE (sRAGE) serum level could be a biomarker for atherosclerosis and subsequent diseases such as cardiovascular disease (CVD). Therefore, we wanted to investigate whether peripheral sRAGE level is associated with new cardiovascular events among patients with CVD using the Cox's regression analysis. METHODS: In this three-year longitudinal cohort study, 1002 in-patients with angiographically proven CVD were included. In 933 patients, sRAGE levels were determined by a commercial available ELISA kit at the time of baseline examination. The combined endpoint was defined as myocardial infarction, stroke/TIA (non-fatal, fatal), and cardiovascular death. For risk analysis, sRAGE values were distributed in quartiles. For generation of adjusted hazard ratios (HR), other risk factors for CVD, such as age, gender, current smoking, body mass index, diabetes, hypertension, dyslipoproteinemia, family history of CVD, severe periodontitis, serum levels for C-reactive protein and interleukin-6, were recorded. RESULTS: 886 patients completed the 3-year follow-up. The overall incidence of the combined endpoint was 16%. Patients with sRAGE levels >838.19 pg/ml (fourth quartile) had the highest incidence of recurrent CVD events (24.9% versus 13.1%, p < 0.0001). In multivariate Cox regression with respect to further confounders for CVD, the association between sRAGE and new CVD events was confirmed (HR = 1.616, 95% CI 1.027-2.544, p = 0.038). CONCLUSIONS: Elevated sRAGE serum level is associated with further adverse events in patients with CVD.
Authors: Andrea Maria Maresca; Luigina Guasti; Sara Bozzini; Christian Mongiardi; Nicolò Tandurella; Rossana Corso; Francesco G Zerba; Alessandro Squizzato; Leonardo Campiotti; Francesco Dentali; Catherine Klersy; Anna M Grandi; Colomba Falcone Journal: Cardiovasc Diabetol Date: 2019-02-12 Impact factor: 9.951
Authors: Lander Egaña-Gorroño; Raquel López-Díez; Gautham Yepuri; Lisa S Ramirez; Sergey Reverdatto; Paul F Gugger; Alexander Shekhtman; Ravichandran Ramasamy; Ann Marie Schmidt Journal: Front Cardiovasc Med Date: 2020-03-10